BioLife Solutions, Inc.

DB:BJX1 Stock Report

Market Cap: €910.2m

BioLife Solutions Management

Management criteria checks 1/4

BioLife Solutions' CEO is Rod de Greef, appointed in Oct 2023, has a tenure of 1.58 years. total yearly compensation is $7.05M, comprised of 10.6% salary and 89.4% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth €4.49M. The average tenure of the management team and the board of directors is 1.6 years and 16.5 years respectively.

Key information

Rod de Greef

Chief executive officer

US$7.0m

Total compensation

CEO salary percentage10.6%
CEO tenure1.6yrs
CEO ownership0.5%
Management average tenure1.6yrs
Board average tenure16.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rod de Greef's remuneration changed compared to BioLife Solutions's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$7mUS$744k

-US$11m

Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$6mUS$199k

-US$18m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$450k

US$388k

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$96m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$1mUS$412k

-US$9m

Sep 30 2021n/an/a

US$5m

Jun 30 2021n/an/a

US$4m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$391k

US$2m

Sep 30 2020n/an/a

US$7m

Jun 30 2020n/an/a

US$16m

Mar 31 2020n/an/a

US$39m

Dec 31 2019US$1mUS$403k

-US$2m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$39m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$490kUS$350k

-US$25m

Compensation vs Market: Rod's total compensation ($USD7.05M) is above average for companies of similar size in the German market ($USD1.35M).

Compensation vs Earnings: Rod's compensation has increased whilst the company is unprofitable.

CEO

Rod de Greef (64 yo)

1.6yrs

Tenure

US$7,046,205

Compensation

Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...

Leadership Team

NamePositionTenureCompensationOwnership
Roderick de Greef
CEO & Chairman1.6yrsUS$7.05m0.49%
€ 4.5m
Troy Wichterman
Chief Financial Officer3.5yrsUS$2.55m0.40%
€ 3.7m
Karen Foster
Chief Quality & Operations Officer1.3yrsUS$1.52m0.42%
€ 3.8m
Aby Mathew
Chairman of Scientific Advisory Board5.4yrsUS$1.73m0.66%
€ 6.0m
Todd Berard
Chief Commercial Officerless than a yearUS$1.13m0.29%
€ 2.6m
Sean Werner
Chief Technology Officerless than a yearno data0.059%
€ 539.1k
Sarah Aebersold
Chief Human Resources Officer4.3yrsno data0.17%
€ 1.6m

1.6yrs

Average Tenure

52yo

Average Age

Experienced Management: BJX1's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Roderick de Greef
CEO & Chairman2.3yrsUS$7.05m0.49%
€ 4.5m
Aby Mathew
Chairman of Scientific Advisory Boardno dataUS$1.73m0.66%
€ 6.0m
Shelly Heimfeld
Member of Scientific Advisory Board18.6yrsno datano data
Scott Burger
Member of Scientific Advisory Board17.7yrsno datano data
Dayong Gao
Member of Scientific Advisory Board18.6yrsno datano data
Andrew Hinson
Member of the Scientific Advisory Boardno dataUS$284.00kno data
Erik Woods
Member of Scientific Advisory Board17.7yrsno datano data
Lizabeth Cardwell
Member of the Scientific Advisory Boardno datano datano data
Amy DuRoss
Independent Lead Director4.1yrsUS$308.04k0.065%
€ 595.4k
Joydeep Goswami
Independent Director3.6yrsUS$271.27k0.10%
€ 931.1k
Colleen Delaney
Member of Scientific Advisory Board16.5yrsno datano data
Catherine Coste
Independent Directorless than a yearno data0.012%
€ 110.6k

16.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: BJX1's board of directors are seasoned and experienced ( 16.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 01:55
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioLife Solutions, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
George ZavoicoB. Riley Securities, Inc.
Matthew HewittCraig-Hallum Capital Group LLC